Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Head & Neck 1

Conditions

Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced or Metastatic Solid Malignancies 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Adenocarcinoma 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × sitravatinib × Clear all
NCT03015740 2024-11-19

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
42 enrolled 14 charts
Genitourinary

Carcinoma, Renal Cell

NCT04518046 2024-06-05

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Mirati Therapeutics Inc.

Phase 1 Completed
22 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT03680521 2023-10-04

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Mirati Therapeutics Inc.

Phase 2 Completed
25 enrolled 22 charts
Genitourinary

Carcinoma, Renal Cell

NCT02219711 2023-03-06

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Mirati Therapeutics Inc.

Phase 1 Completed
193 enrolled
GenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡